2 huge investment risks I’m worried about in 2025

Ken Hall looks at two big investment risks that are keeping him up at night as we enter 2025 with the UK stock market delicately poised.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Chalkboard representation of risk versus reward on a pair of scales

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investing is risky as well as rewarding, and I’ve been thinking about two investment risks that I’m worried about in particular.

2024 was a fairly good year for the UK share market with the FTSE 100 gaining nearly 6%. But now, with the year becoming a distant memory, my mind has turned to protecting my portfolio in the months ahead.

While I’m optimistic about investing in UK stocks, there’s plenty of uncertainty in the world and I’m considering buying GSK (LSE: GSK) shares as a result. But first, let’s look at those two risks.

Should you invest £1,000 in Gsk right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Gsk made the list?

See the 6 stocks

Geopolitics

Last year was the year of elections. A big chunk of the world’s population headed to the polls including the US where Donald Trump claimed victory to secure a second term.

Analysts are watching carefully to see what policy changes the new administration will put in place. Many are tipping that deregulation could pave the way for more investment activity including mergers and acquisitions.

On the other hand, tariffs are widely expected but just how much and on which products are unclear for now. These could well stifle global and UK economic growth in 2025, despite the British government’s efforts to boost spending in key areas like housing.

Inflation pressures

Stubborn inflation is also weighing on my mind. Potential trade policy changes in the US could raise prices just as it had seemed inflation was coming under control.

Similarly, increased UK government spending could increase demand (and prices). Any large surprises may well spook investors as that could well mean the Bank of England takes a different interest rate policy path versus expectations.

Where I want to invest

These are just two investment risks that are on my mind right now and I’m looking to add more defensive exposure to my portfolio.

The Footsie boasts a number of large pharmaceutical companies, including AstraZeneca and GSK. The latter is the one that I’ve been narrowing in on in recent weeks as a potential buy.

The resiliency of the sector is certainly one part of my thinking. However, I also like that it’s a UK-based company with global footprint including strong links to the US.

Pharmaceutical companies can often pass on rising costs quite effectively to their customers, which can provide something of an inflation hedge. I also think the company’s track record as a dividend payer shows it can be investor-friendly in returning capital.

Key risks

Of course, GSK isn’t immune to risks. While the company has been actively building its research and development pipeline, there’s always uncertainty surrounding drug approvals as well as fierce competition from rivals.

Customers may also eventually reject price increases, which could hurt profitability, as could fierce competition from rivals.

Valuation

Yet the company’s 13.9 price-to-earnings (P/E) ratio is below the 14.5 average for the Footsie and looks a little cheap for a large player in a defensive industry. Rival AstraZeneca’s shares are trading at a multiple of 32, albeit it does have a £167bn market cap compared to GSK’s £56bn.

I’m certainly considering GSK shares as a way to help hedge against some of the investment risks I see looming in 2025. It’s one of the names up the top of my list to buy when I gather the funds to buy.

Pound coins for sale — 31 pence?

This seems ridiculous, but we almost never see shares looking this cheap. Yet this Share Advisor pick has a price/book ratio of 0.31. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 31p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 10%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ken Hall has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our best passive income stock ideas

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

More on Investing Articles

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

With Cash ISA changes coming, could now be the time to consider buying shares?

Changes to the Cash ISA could lead to greater investment in the stock market. This could be a good thing…

Read more »

Investing Articles

These FTSE 100 dividend shares just got cheaper, thanks to President Trump!

Investors buying dividend shares can lock in bigger long-term yields when share prices take a tumble. These two just did…

Read more »

Investing Articles

At a 52-week low but Taylor Wimpey shares are forecast to rise 35% in a year and yield almost 9%!

Taylor Wimpey shares have had a rough ride but Harvey Jones says analyst forecasts are upbeat, while there is also…

Read more »

Investing Articles

As copper prices surge, Glencore shares are a steal at 270p

Andrew Mackie believes the extraordinary dislocation occurring in copper markets will be very supportive for the Glencore share price.

Read more »

Investing Articles

2 cheap shares to consider as Trump shocks markets

Dr James Fox examines several cheap shares, on paper at least, as markets experience a broad sell-off in reaction to…

Read more »

Investing Articles

10% dividend yield! Here’s a FTSE 100 share to consider in April for passive income

This FTSE 100 stock just soared past the 10% yield mark, making it a potentially lucrative option for investors targeting…

Read more »

Young black woman using a mobile phone in a transport facility
Investing Articles

3 FTSE 100 safe haven stocks to consider as trade wars bite

I'm confident in the long-term outlook for the FTSE index of stocks. But these blue chips may protect investors from…

Read more »

Investing Articles

Here’s how Trump tariffs could hand us some top passive income bargains

As tariff terror grips the stock market, it's time for passive income investors to steel our nerves and look for…

Read more »